首页> 外文期刊>Endocrine pathology >Immunohistochemical expression of neuroendocrine secretory protein-55 (NESP-55) in pituitary adenomas.
【24h】

Immunohistochemical expression of neuroendocrine secretory protein-55 (NESP-55) in pituitary adenomas.

机译:垂体腺瘤中神经内分泌分泌蛋白55(NESP-55)的免疫组织化学表达。

获取原文
获取原文并翻译 | 示例
       

摘要

Neuroendocrine secretory protein-55 (NESP-55) is a recently described member of the chromogranin family and appears to be a marker of the constitutive secretory pathway in certain neural, neuroendocrine, and endocrine cell types. It has been shown to be selectively expressed in tumors differentiating towards the adrenal chromaffin and pancreatic islet cell phenotypes. The highest levels of NESP-55 expression, at least in animals, appear to be in the adrenal medulla and the pituitary gland. However, very little is known about the status of NESP-55 expression in pituitary adenomas. We therefore studied the immunohistochemical profile of NESP-55 expression in a series of 30 well-characterized pituitary adenomas (five each of FSH/LH and ACTH, four GH, three TSH, seven prolactin, and six null cells). All tumors were positive for one or more generic marker(s) (chromogranin A, synaptophysin, neuron-specific enolase) of neuroendocrine differentiation. All pituitary adenomas selected for study were stained for NESP-55 with appropriate positive and negative controls. NESP-55 immunoreactivity, seen as brown finely granular cytoplasmic staining of the tumor cells with prominent perinuclear accentuation, was graded as focal (<10% tumor cells staining), moderate (10-50% tumor cells staining), and diffuse (>50% tumor cell staining). Four of seven prolactinomas were positive for NESP-55 (one focal, two moderate, and one diffuse). Two of four GH adenomas were also positive (one focal and one diffuse) while only 1/5 FSH tumors showed a moderately intense immunoreactivity. All other pituitary adenomas were completely negative for NESP-55. Our results indicate that, in human pituitary adenomas, NESP-55 has a more restricted pattern of expression than that of chromogranins A and B. Since immunohistochemical expression of NESP-55 is largely confined to prolactinomas and GH adenomas, it raises the possibility that NESP-55 may somehow be involved in the secretory pathways of these specific cell types.
机译:神经内分泌分泌蛋白55(NESP-55)是嗜铬粒蛋白家族的最新成员,在某些神经,神经内分泌和内分泌细胞类型中似乎是组成型分泌途径的标志物。已经显示它在分化为肾上腺嗜铬细胞和胰岛胰岛细胞表型的肿瘤中选择性表达。至少在动物中,NESP-55表达的最高水平似乎出现在肾上腺髓质和垂体中。但是,关于垂体腺瘤中NESP-55表达的状态知之甚少。因此,我们研究了一系列30个特征明确的垂体腺瘤(5个FSH / LH和ACTH,4个GH,3个TSH,7个催乳激素和6个空细胞)中NESP-55表达的免疫组织化学谱。所有肿瘤对神经内分泌分化的一种或多种通用标记(嗜铬粒蛋白A,突触素,神经元特异性烯醇化酶)呈阳性。选择用于研究的所有垂体腺瘤,用适当的阳性和阴性对照对NESP-55染色。 NESP-55免疫反应性(被视为具有明显核周增强的肿瘤细胞的褐色细颗粒胞质染色)被分类为局灶性(<10%肿瘤细胞染色),中度(10-50%肿瘤细胞染色)和弥散性(> 50 %肿瘤细胞染色)。 7例催乳素瘤中有4例NESP-55阳性(1例,2例中度和1例弥漫性)。四个GH腺瘤中的两个也呈阳性(一个灶性,一个弥散性),而只有1/5 FSH肿瘤显示出中等强度的免疫反应性。所有其他垂体腺瘤NESP-55完全阴性。我们的结果表明,在人垂体腺瘤中,NESP-55的表达模式比嗜铬粒蛋白A和B更为严格。由于NESP-55的免疫组织化学表达主要局限于泌乳素瘤和GH腺瘤,因此增加了NESP-55的表达。 -55可能以某种方式参与了这些特定细胞类型的分泌途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号